Protective effect of Shengmai injection on myocardial endothelial cell glycoprotein detachment after myocardial ischemia-reperfusion injury in isolated rat hearts
Restricted accessResearch articleFirst published online October, 2021
Protective effect of Shengmai injection on myocardial endothelial cell glycoprotein detachment after myocardial ischemia-reperfusion injury in isolated rat hearts
To investigate effects of Shengmai injection (SMI) postconditioning on myocardial ischemia-reperfusion injury (MIRI) in isolated rat hearts.
Materials and methods:
A total of thirty isolated hearts were randomly divided into three groups: Sham group, I/R group and SMI group. Sham group was continuously perfused with K-H solution for 120 minutes. I/R group and SMI group were given balanced perfusion for 30 min followed by reperfusion for 60 min, with an interval of 30 min, and those in the SMI group were given postconditioning with 1% SMI during the first 10 min of reperfusion. The left ventricular function, markers of myocardial injury, endothelial cell injury and oxidative stress injury were measured at 30 minutes after equilibration (t0), 30 minutes after ischemia (t2) and 60 minutes after reperfusion (t3).
Results:
The results showed that there was no significant difference for all observation indexes at t0. Compared with the Sham group, real portfolio project and coronary arterial flow rate and the activity of superoxide dismutase were significantly decreased in the I/R group, whereas those in the SMI group were significantly higher. Left ventricular end-diastolic pressure, the concentrate of malondialdehyde, lactate dehydrogenase, cTn-I, hyaluronic acid, heparin sulphate, syndecan-1 in the I/R group were markedly higher than those in the Sham group, whereas those in the SMI group were significantly lower.
Conclusion:
In summary, the present study indicated that 1% SMI postconditioning can alleviate the detachment of endothelial cell glycoprotein envelope induced by myocardial ischemia-reperfusion injury, and its mechanism is probably related to the inhibition of the oxidative stress injury.
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2017; 390: 1151–1210.
2.
HeuschGGershB.The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J2017; 38: 774–784.
3.
LibbyP.Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med2013; 368: 2004–2013.
TurerAHillJ.Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol2010; 106: 360–368.
6.
HowardTGreer-ShortASatroplusT, et al. CaMKII-dependent late Na current increases electrical dispersion and arrhythmia in ischemia-reperfusion. Am J Physiol Heart Circ Physiol2018; 315: H794–H801.
7.
SedovaKGalinyteVArteyevaN, et al. Multi-lead vs single-lead T-T interval measurements for prediction of reperfusion ventricular tachyarrhythmias. J Cardiovasc Electrophysiol2019; 30: 2090–2097.
8.
LesnefskyEChenQTandlerB, et al. Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies. Annu Rev Pharmacol Toxicol2017; 57: 535–565.
9.
EltzschigHEckleT.Ischemia and reperfusion–from mechanism to translation. Nat Med2011; 17: 1391–1401.
10.
PiperHMeuterKSchäferC.Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg2003; 75: S644–S648.
11.
LiuYYangHJiaG, et al. The synergistic neuroprotective effects of combined rosuvastatin and resveratrol pretreatment against cerebral ischemia/reperfusion injury. J Stroke Cerebrovasc Dis2018; 27: 1697–1704.
12.
FrankABonneyMBonneyS, et al. Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc Anesth2012; 16: 123–132.
13.
ZhaoZCorveraJHalkosM, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol2003; 285: H579–H588.
14.
PagelP.Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J Cardiothorac Vasc Anesth2008; 22: 753–765.
15.
LiuHWangCQiaoZ, et al. Protective effect of curcumin against myocardium injury in ischemia reperfusion rats. Pharm Biol2017; 55: 1144–1148.
16.
GwagHKimEParkT, et al. Cardioprotective effects of intracoronary morphine in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a prospective, randomized trial. J Am Heart Assoc2017; 6: e005426.
17.
ReddyAVidalMStephenS, et al. The conversion ratio from intravenous hydromorphone to oral opioids in cancer patients. J Pain Symptom Manage2017; 54: 280–288.
18.
Santos-GallegoCVahlTGoliaschG, et al. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. Circulation2016; 133: 954–966.
19.
ChenJYaoYChenH, et al. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database Syst Rev2012; 11: CD005052.
20.
WeiXYeXXieY, et al. Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke. Zhongguo Zhong Yao Za Zhi2011; 36: 2789–2792.
21.
LiJWangHLiS, et al. Shenmai injection for chronic pulmonary heart disease: a systematic review and meta-analysis. J Altern Complement Med2011; 17: 579–587.
22.
BansalSSanghaKKhatriP.Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs2013; 13: 57–69.
23.
LiuQKouJYuB.Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-κB activation. Neurochem Int2011; 58: 119–125.
24.
ChenZLuTYueX, et al. Neuroprotective effect of ginsenoside Rb1 on glutamate-induced neurotoxicity: with emphasis on autophagy. Neurosci Lett2010; 482: 264–268.
25.
LeeKJungSChoiS, et al. Effects of ginsenoside Re on LPS-induced inflammatory mediators in BV2 microglial cells. BMC Complement Altern Med2012; 12: 196.
26.
ThompsonLFrasierCSloanR, et al. Pulmonary instillation of multi-walled carbon nanotubes promotes coronary vasoconstriction and exacerbates injury in isolated hearts. Nanotoxicology2014; 8: 38–49.
27.
MoensAClaeysMTimmermansJ, et al. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol2005; 100: 179–190.
MulivorALipowskyH.Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol2002; 283: H1282–1291.
30.
MulivorALipowskyH.Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol2004; 286: H1672–1680.
31.
ChappellDJacobMHofmann-KieferK, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology2007; 107: 776–784.
32.
ChappellDJacobMHofmann-KieferK, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res2009; 83: 388–396.
33.
Rubio-GayossoIPlattsSDulingB.Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol2006; 290: H2247–2256.
34.
LiXChenHJiaW, et al. A metabolomics-based strategy for the quality Sham of traditional chinese medicine: Shengmai injection as a case study. Evid Based Complement Alternat Med2013; 2013: 836179.
35.
LiuXTanWYangF, et al. Shengmai injection reduces apoptosis and enhances angiogenesis after myocardial ischaemia and reperfusion injury in rats. Biomed Pharmacother2018; 104: 629–636.
36.
YangHLiLZhouK, et al. Shengmai injection attenuates the cerebral ischemia/reperfusion induced autophagy via modulation of the AMPK, mTOR and JNK pathways. Pharm Biol2016; 54: 2288–2297.
37.
QueisserNSchuppN.Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. Free Radic Biol Med2012; 53: 314–327.
38.
ThamYBernardoBOoiJ, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol2015; 89: 1401–1438.
39.
ZhangJWangXVikashV, et al. ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev2016; 2016: 4350965.
40.
WuBLinRDaiR, et al. Valsartan attenuates oxidative stress and NF-κB activation and reduces myocardial apoptosis after ischemia and reperfusion. Eur J Pharmacol2013; 705: 140–147.
41.
KhoshjouFDadrasF.Mitochondrion and its role in diabetic nephropathy. Iran J Kidney Dis2014; 8: 355–358.
42.
BraunersreutherVJaquetV.Reactive oxygen species in myocardial reperfusion injury: from physiopathology to therapeutic approaches. Curr Pharm Biotechnol2012; 13: 97–114.
43.
LeiSLiHXuJ, et al. Hyperglycemia-induced protein kinase C β2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling. Diabetes2013; 62: 2318–2328.
44.
FaríasJMolinaVCarrascoR, et al. Antioxidant therapeutic strategies for cardiovascular conditions associated with oxidative stress. Nutrients2017; 9: 996.
